CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death ...
LONDON, May 11 (Reuters) - AstraZeneca Plc's experimental heart drug Brilinta has beaten Sanofi-Aventis SA and Bristol-Myers Squibb Co's blockbuster Plavix in a pivotal clinical trial, lifting its ...
A phase 3 study of AstraZeneca’s ceralasertib has missed its primary endpoint, dealing another blow to efforts to use a synthetic lethal mechanism to overcome resistance to immuno-oncology drugs. The ...
AstraZeneca (NASDAQ:AZN) has initiated a Phase 3 study to evaluate the use of inhaled triple-combination therapy Breztri Aerosphere on severe cardiopulmonary outcomes, including death, in people with ...
(RTTNews) - Biocartis Group NV, a Belgium-based molecular diagnostics company, announced Wednesday that it has entered into an agreement with British drug major AstraZeneca Plc. (AZN, AZN.L) for the ...
Endometrial02, researchers want to see whether Enhertu can replace current standard-of-care chemotherapy for patients with HER2-expressing tumors.
LONDON, Nov 8 (Reuters) - An experimental antidepressant that works by calming nicotine receptors in the brain failed to help patients in a late-stage trial, disappointing investor hopes for ...
Thinly traded nano cap Trovagene (TROV) is up 10% premarket on light volume in response to its announcement of an agreement with AstraZeneca under which it will provide its Trovera urine ctDNA ...
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England. 2014 File Photo / Agence France-Presse CHICAGO — Treating breast cancer patients with AstraZeneca’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback